Melanotan 2 Peptide
The sibling no sponsor ever developed and no regulator ever approved. Its published human record is substantially adverse-event case reports, which is a sentence worth reading twice.
Choose your pack
For research use only. Not for human or veterinary use.
What Melanotan 2 Peptide is
The plain-language version, first.
The shortcut version of the tanning peptide, and the one medicine abandoned.
Melanotan 2 is a cyclic seven amino acid analogue of alpha melanocyte stimulating hormone that acts as a non-selective agonist at melanocortin receptors including MC1R, MC3R and MC4R. It was never taken through clinical development by any sponsor, is approved in no country, and its human literature consists largely of case reports describing adverse events.
Same family as the approved implant, opposite biography.
Melanotan-2 is a shortened cyclic analogue of alpha-MSH: more potent, less selective, and abandoned by legitimate development decades ago.
No sponsor carried it forward. No regulator anywhere has approved it. It exists today purely as a grey-market product.
The cyclic structure that makes it potent also makes it promiscuous across the melanocortin receptor family, hitting departments its approved sibling was selected to avoid.
Which is precisely why one sibling has a drug label and the other has case reports.
The difference between MT-1 and MT-2 is the difference between selectivity and reach, and the file below shows what reach costs.
What is Melanotan 2?
Mechanism studied, not outcome promised.
Agonises MC1R, MC3R, MC4R and MC5R. Pigmentation, appetite, sexual function and autonomic pathways engaged simultaneously, in proportions that vary between people.
A molecule pressing four receptors at once does not have a clean dose-response for any one of them, which is why reported effects are so varied and so hard to predict.
Less selective than its approved sibling, and the extra receptors are the problem.
Recall the melanocortin family runs pigmentation, appetite and arousal signalling through related receptors.
MT-2's cyclic structure grips broadly across them. Broad grip means the pigmentation signal arrives with passengers.
The passengers are documented: nausea, appetite effects, spontaneous arousal effects, and the pigmentation itself arriving unevenly, with darkening moles a recurring clinical observation.
Its arousal-signalling activity is literally how PT-141 was discovered, as a metabolite of this molecule during trials that were then redirected.
Here's the honest part.
A molecule can be potent, interesting and abandoned for cause all at once. The abandonment was not an accident of funding. The selectivity problem was the reason.
The research so far for Melanotan 2 Peptide
Where the evidence is thin, we say so.
Receptor pharmacology, animal work, and a case report literature written by clinicians treating people who used it outside medical supervision.
Any completed clinical trial. Any approval anywhere. Any dose-response data in humans. Any denominator that would let you estimate how often the reported harms occur.
No sponsor ever developed Melanotan 2. There is no completed clinical programme, no approval application anywhere and no regulatory assessment. Melanotan 1 came out of the same laboratory and went through the entire process to FDA approval in 2019. The published human record for this one is case reports, and those case reports include melanoma, rhabdomyolysis and posterior reversible encephalopathy syndrome.
The human literature is mostly case reports of things going wrong.
The published human record on MT-2 has an unusual and telling shape.
Early small trials exist from the 1990s and 2000s, before development stopped. What has accumulated since is case reports, and case reports in medicine are how bad outcomes get documented.
Darkening and changing moles feature repeatedly, which given the mechanism is exactly what a dermatologist would predict and worry about.
No approval anywhere. No sponsor. No safety programme watching the grey market that actually uses it.
The approved sibling proves this family can produce a real medicine. This molecule is the version of the story where nobody finished the work, and the case-report literature is what unfinished looks like in humans.
Have a look at the vial sizes we keep in stock.
Melanotan 2 Peptide specs
The chemistry, exactly as released.
Who studies Melanotan 2 Peptide
Who tends to order this one, and why.
A research compound does not have one audience. It has a handful of rooms where the same question keeps coming up, and the question is a different question in each of them.
Melanocortin pharmacology
The non-selective profile across MC1R, MC3R, MC4R and MC5R makes it a tool compound for probing multiple receptors at once, which is also its clinical problem.
Dermatology
The case literature on changes in melanocytic naevi and melanoma. Melanotan 1, the more selective analogue, carries dermatologic monitoring in its approved label.
Toxicology and emergency medicine
Rhabdomyolysis and posterior reversible encephalopathy syndrome are the published serious presentations, and they came from clinicians treating them.
Nobody, in clinical development
No sponsor has ever run a completed clinical programme on this compound. That is the honest answer for this row.
Sold for laboratory research only. This is not guidance for personal use, and nothing here is a recommendation.
Melanotan 2 Peptide backstory
How it got here.
The Arizona melanocortin programme was studying pigmentation biology, not building a tanning product. Alpha-MSH analogues came out of it, engineered for stability and potency at melanocortin receptors.
Melanotan 1 found a genuine unmet medical need in erythropoietic protoporphyria, a rare disorder where patients cannot tolerate daylight, and a company committed to the decade of trials required to get it approved. Melanotan 2 found a market instead of a sponsor.
Its non-selective receptor profile produced effects people wanted, it spread through informal channels, and the clinical development that would have characterised its risks never happened. What filled that gap was case reports, written by clinicians treating the consequences.
- 1
One laboratory, two molecules
University of Arizona melanocortin research in the 1980s produced both Melanotan 1 and Melanotan 2 as engineered alpha-MSH analogues.
- 2
One found a sponsor
Clinuvel took Melanotan 1 through clinical trials in erythropoietic protoporphyria to European and then FDA approval in October 2019.
- 3
One found a market
Melanotan 2 was never developed. It spread through informal channels and the characterisation of its risks came from clinicians writing case reports.
Buying Melanotan 2 Peptide in Canada
What ships, how fast, and the paperwork.
The hard part of buying research material is almost never the compound. It is the logistics. What leaves the building, how fast it moves, and what is in the box beside the vial. Here is ours, plainly.
Same day out of British Columbia
Our building, our cold packs, our people, and nothing sitting in a customs queue while you refresh a tracking page.
Then into the fridge
Keep it cold and keep it dark. Sealed and freeze-dried it handles a rough trip without ice. Once it lands, fridge.
The case literature is the safety data
There is no trial safety profile for this compound because there was never a trial. What exists instead are published case reports including melanoma and changes in existing moles, rhabdomyolysis, and posterior reversible encephalopathy syndrome. We would rather you read that here than not at all.
Stuff people ask about Melanotan 2 Peptide
If your question is not here, email us. Real human answers.
No completed clinical development programme exists. No sponsor took it forward, there is no phase 3, no approval application in any country and no regulator has ever assessed it. Melanotan 1, which came out of the same 1980s Arizona research, went through the full process and was approved by the FDA in October 2019.
The published human record is largely case reports, and the signals in it include melanoma and changes in existing melanocytic naevi, rhabdomyolysis, and posterior reversible encephalopathy syndrome. Case reports have no denominator so they cannot tell you how often these occur, but they do establish that they have happened and that clinicians thought them worth publishing.
Receptor selectivity, and regulatory history. Melanotan 1 is relatively selective for MC1R, the pigmentation receptor, and is an approved medicine. Melanotan 2 is non-selective, agonising MC1R, MC3R, MC4R and MC5R, which brings appetite, sexual function and autonomic pathways into play alongside pigmentation. It has no approval anywhere.
Because of the mechanism. This compound acts directly on melanocytes, the cells melanoma arises from. A melanocyte-stimulating drug appearing in melanoma case reports is not a coincidental pairing, it is the specific risk you would design monitoring around. Melanotan 1, the more selective and approved analogue, carries dermatologic monitoring requirements in its FDA label for that reason.
It is not an approved drug in any country and is not authorised for human use. Regulators in several jurisdictions have issued warnings about products containing it. Everything on this site is supplied for research use only and not for human consumption.
Because it engages four melanocortin receptors at once rather than one. MC1R governs pigmentation, MC3R and MC4R are central and involved in energy balance and appetite, MC4R also in sexual function, and MC5R sits in exocrine glands. A molecule pressing all of those simultaneously has no clean dose-response for any single one, so the balance of effects differs between individuals.
Good pairing options with Melanotan 2 Peptide
What researchers stack alongside it.
Pairing is where research gets ahead of itself. These are the compounds researchers put in the same order as Melanotan 2 Peptide, which is a statement about ordering habits, not about evidence. Two things in one cart have not been studied together unless somebody studied them together.
Without a zinc atom it is completely inert. Not less active. Inert. The metal is not a supporting player here, it is half the molecule's identity.
It has no sequence and no CAS number, because it is not a molecule. It is an extract of calf thymus, still in clinical use across Russia, and that combination is genuinely unusual.
Order Melanotan 2 Peptide right now
One last look before you decide.
Freeze-dried, COA on the page, ships cold
If you are researching Melanotan 2 Peptide and you want a source you do not have to second-guess, start with the paperwork on this page. For research use only.
Not for human consumption. Not approved by Health Canada or any other regulatory body.
Page last updated August 19, 2026
People also search for Melanotan 2 Peptide
Other names for the same compound.